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Abstract: Protein kinase B (Akt) is a key enzyme in the insulin signalling cascade, required for
insulin-stimulated NO production in endothelial cells (ECs). Previous studies have suggested
that AMP-activated protein kinase (AMPK) activation stimulates NO synthesis and enhances
insulin-stimulated Akt activation, yet these studies have largely used indirect activators of AMPK.
The effects of the allosteric AMPK activator A769662 on insulin signalling and endothelial function
was therefore examined in cultured human macrovascular ECs. Surprisingly, A769662 inhibited
insulin-stimulated NO synthesis and Akt phosphorylation in human ECs from umbilical veins
(HUVECs) and aorta (HAECs). In contrast, the AMPK activators compound 991 and AICAR had
no substantial inhibitory effect on insulin-stimulated Akt phosphorylation in ECs. Inhibition of
AMPK with SBI-0206965 had no effect on the inhibition of insulin-stimulated Akt phosphorylation
by A769662, suggesting the inhibitory action of A769662 is AMPK-independent. A769662 decreased
IGF1-stimulated Akt phosphorylation yet had no effect on VEGF-stimulated Akt signalling in
HUVECs, suggesting that A769662 attenuates early insulin/IGF1 signalling. The effects of A769662
on insulin-stimulated Akt phosphorylation were specific to human ECs, as no effect was observed
in the human cancer cell lines HepG2 or HeLa, as well as in mouse embryonic fibroblasts (MEFs).
A769662 inhibited insulin-stimulated Erk1/2 phosphorylation in HAECs and MEFs, an effect that
was independent of AMPK in MEFs. Therefore, despite being a potent AMPK activator, A769662 has
effects unlikely to be mediated by AMPK in human macrovascular ECs that reduce insulin sensitivity
and eNOS activation.
Keywords: AMP-activated protein kinase; protein kinase B; Akt; insulin signalling; A769662;
endothelial function
1. Introduction
Endothelial cells (ECs) are essential for modulation of vascular homeostasis and signal
transduction [1], including the production and regulation of vascular tone, modulation of inflammatory
responses and maintenance of an anti-atherogenic phenotype of vascular smooth muscle cells
(VSMCs) [1]. Being the downstream target of phosphoinositide (PI) 3-kinase (PI3K), protein kinase
B (Akt) is one of the key kinases regulating cell survival, cell-cycle progression and metabolism [2].
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Under physiological conditions, insulin [3], VEGF [4] or IGF1 [5] stimulation rapidly leads to increased
Akt activity by increasing Ser473 and Thr308 phosphorylation.
In healthy subjects, insulin acts as a vasodilator, stimulating calcium-independent NO synthesis
in cultured human aortic ECs (HAECs) through Akt-mediated phosphorylation of endothelial nitric
oxide synthase (eNOS) Ser1177 and Ser615 [6]. However, in murine models of diabetes and people with
diabetes, impaired insulin-stimulated blood flow and NO bioavailability have been demonstrated [7].
Decreased NO bioavailability leads to endothelial dysfunction in animal models and human subjects,
increasing risk of cardiovascular events and pro-inflammatory signalling in the vasculature [8].
AMP-activated protein kinase (AMPK) is a heterotrimeric serine/threonine protein kinase
sensitive to intracellular AMP levels which acts as a master regulator of energy metabolism [9,10].
AMPK is activated in response to an increase in the intracellular (AMP + ADP):ATP ratio
and simultaneous AMPKα Thr172 phosphorylation by the upstream kinases liver kinase B1 or
calcium/calmodulin-dependent protein kinase kinase β [9,10]. Activated AMPK inhibits anabolic
processes which consume ATP [9,10], reduces inflammation [11,12], inhibits endothelial cell
proliferation [13], stimulates mitochondrial biogenesis [14], and increases insulin sensitivity [9,15],
making it an attractive pharmacological target for diabetes and cardiovascular pathologies [10]. There
are 12 differentially expressed AMPK isoforms, each composed of catalytic α1/α2, and regulatory
β1/β2 and γ1/γ2/γ3 subunits [9,10], allowing a specialised cellular and systemic response to different
metabolic stimuli [10].
Previous studies have reported that AMPK activation improved insulin sensitivity and energy
homeostasis, and attenuated inflammatory signalling in insulin-sensitive tissues, such as muscle [14],
liver [16,17] and adipose tissue [11,18] as well as ECs [12,15]. Several AMPK activators have been
shown to increase NO synthesis in HAECs in an AMPK-dependent manner [10]. Nevertheless, it is
unclear whether all AMPK activators improve insulin sensitivity and vascular function, as previous
studies have largely been conducted using a variety of compounds that activate AMPK by altering
cellular nucleotide ratios, including rosiglitazone, resveratrol, metformin and canagliflozin or mimic
AMP, such as AICAR (5-amino-4-imidazolecarboxamide ribonucleoside) [12,19–22].
In the last 15 years, there has been considerable effort to develop AMPK-selective small-molecule
activators, resulting in the development of A769662 [23], the discovery of salicylate as an AMPK
activator and, more recently, the development of compound 991—a compound 5–10-fold more potent
than A769662 [24]. A769662 is an allosteric activator that binds complexes containing AMPKβ1,
also inhibiting AMPKα Thr172 dephosphorylation [24,25]. Since being first described as an AMPK
activator, some AMPK-independent effects of A769662 have been reported [26–29], yet it remains
a commonly utilised pharmacological tool for selective AMPK activation. The effects of A769662
on insulin signalling and insulin-stimulated Akt/eNOS axis activation in primary human ECs were
therefore determined.
2. Results
2.1. Insulin-Stimulated Signalling and NO Production are Reduced by A769662 in Human Endothelial Cells
Stimulation of HUVECs with concentrations of insulin above 0.1 µM robustly stimulated
phosphorylation of Akt at Ser473 and Thr308 (Supplementary Figure S1), similar to concentrations
of insulin previously demonstrated to be required for insulin-stimulated NO synthesis in cultured
endothelial cells [30]. All subsequent experiments were therefore conducted using 1 µM insulin.
To examine the effect of A769662 on HUVEC insulin signalling, cells were preincubated in the presence
or absence of A769662 prior to stimulation with insulin and NO synthesis and the extent of Akt
phosphorylation assessed. Insulin modestly increased NO synthesis, yet insulin-stimulated NO
synthesis was lost upon preincubation with A769662 (Figure 1A).
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Figure 1. The effect of A769662 on insulin-stimulated NO production and Akt phosphorylation in 
HUVECs. (A) HUVECs were stimulated with A769662 (50 µM, 45 min) prior to insulin (1 µM, 15 min), 
conditioned media collected and NO production assessed. Data (mean ± SEM) shown from three 
independent replicates. (B–E) HUVECs were stimulated with A769662 (50 µM, 45 min) or AICAR (2 
mM, 45 min) prior to insulin (51 µM, 15 min) and cell lysates prepared. Proteins were resolved by 
SDS-PAGE and immunoblotted with the antibodies indicated. (B) Representative immunoblots from 
three biological replicates with molecular weight markers indicated. Phospho-Akt Thr308 protein 
levels were assessed by stripping and re-probing the membranes. Densitometric quantification of (C) 
ACC, (D) Akt Ser473 and (E) Akt Thr308 phosphorylation normalised to β-tubulin or Akt (mean ± 
SEM). * p < 0.05, ** p < 0.01, relative to absence of insulin. # p < 0.05, ## p <0.01 relative to absence of 
AMPK activator. 
A769662 (50 µM, 45 min) increased AMPK activity, assessed by immunoblotting of AMPK-
specific ACC (acetyl CoA carboxylase) Ser79 phosphorylation (Figure 1B,C), yet insulin had no effect 
on ACC phosphorylation. The inhibition of NO production was associated with markedly reduced 
insulin-stimulated phosphorylation of Akt at Ser473 and Thr308 (Figure 1D,E). In contrast, the AMPK 
activator AICAR, which is converted to the AMP mimetic ZMP in cells, increased basal and insulin-
stimulated Akt Ser473 and Thr308 phosphorylation (Figure 1D,E), despite activating AMPK to a 
similar degree as assessed by ACC Ser79 phosphorylation (Figure 1C). Furthermore, the direct AMPK 
activator compound 991, which allosterically activates AMPK at the same site as A769662 [31], had 
no effect on basal or insulin-stimulated Akt Thr308 phosphorylation, and only modestly reduced 
insulin-stimulated Akt Ser473 phosphorylation by 10% despite activating AMPK to a similar extent 
(Figure 2). 
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A769662 (50 µM, 45 min) increased AMPK activity, assessed by immunoblotting of AMPK-specific
ACC (acetyl CoA carboxylase) Ser79 phosphorylation (Figure 1B,C), yet insulin had no effect on
ACC phosphorylation. The inhibition of NO production was associated with markedly reduced
insulin-stimulated phosphorylation of Akt at Ser473 and Thr308 (Figure 1D,E). In contrast, the AMPK
activator AICAR, which is converted to the AMP mimetic ZMP in cells, increased basal and
insulin-stimulated Akt Ser473 and Thr308 phosphorylation (Figure 1D,E), despite activating AMPK
to a similar degree as assessed by ACC Ser79 phosphorylation (Figure 1C). Furthermore, the direct
AMPK activator compound 991, which allosterically activates AMPK at the same site as A769662 [31],
had no effect on basal or insulin-stimulated Akt Thr308 phosphorylation, and only modestly reduced
insulin-stimulated Akt Ser473 phosphorylation by 10% despite activating AMPK to a similar extent
(Figure 2).
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Figure 2. The effect of compound 991 on insulin-stimulated Akt phosphorylation in HUVECs. 
HUVECs were stimulated with compound 991 (5 µM, 45 min) prior to insulin (1 µM, 15 min) and cell 
lysates prepared. Proteins were resolved by SDS-PAGE and immunoblotted with the antibodies 
indicated. (A) Representative immunoblots from three biological replicates with molecular weight 
markers indicated. Phospho-Akt Thr308 protein levels were assessed by stripping and re-probing the 
membranes. Densitometric quantification of (B) ACC Ser79, (C) Akt Ser473 and (D) Akt Thr308 
phosphorylation normalised to ACC or Akt (mean ± SEM). *** p < 0.001, **** p <0.0001 relative to 
absence of insulin. # p <0.05 relative to absence of compound 991. 
To examine the relationship between AMPK activation and inhibition of insulin-stimulated Akt 
phosphorylation by A769662, the concentration dependence of either effect of A769662 was assessed. 
Significant A769662-mediated stimulation of ACC phosphorylation was achieved with 50–100 µM 
A769662 (Figure 3A,B). A769662 decreased both insulin-stimulated Akt Ser473 and Thr308 
phosphorylation in HUVECs in a concentration-dependent manner (Figure 3A), whereby 100 µM 
A769662 significantly inhibited Akt S473 phosphorylation and the statistical significance of insulin-
stimulated Akt phosphorylation at either site was lost at concentrations above 10 µM A769662 (Figure 
3C,D). 
Furthermore, the time dependence of the inhibitory effect of A769662 on insulin-stimulated Akt 
phosphorylation was assessed. A769662 (50 µM) rapidly stimulated ACC phosphorylation in 
HUVECs within 5 min, an effect that was sustained for at least 2 h (Figure 3E,F). The inhibitory effect 
of A769662 on insulin-stimulated Akt Ser473 phosphorylation occurred similarly rapidly within 5 
min and was sustained for 1 h (Figure 3E,G). 
To determine whether the inhibition of insulin-stimulated Akt phosphorylation in ECs was 
AMPK-dependent, similar experiments were conducted after prior incubation in the SBI-0206965, 
which has recently been described as a selective inhibitor of AMPK [32]. Preincubation with 30 µM 
SBI-0206965 completely inhibited A769662-stimulated ACC Ser79 phosphorylation (Figure 4A,B), yet 
had no effect on the inhibition of insulin-stimulated Akt phosphorylation at Ser473 or Thr308 (Figure 
4A,C,D), further indicating that the inhibitory effect of A769662 was AMPK-independent. 
i re 2. i
l t ith compound 91 (5 µM, 45 min) prior to insulin (1 µM, 15 min) and
cell ly ates repared. Proteins wer resolved by SDS-PAGE and i unoblo ted it antibo ies
i i t . i l i re li t it olec l r eig t
r Phospho-Akt Thr308 protein levels w re as essed by stripping and re-probing
th embranes. Densitometric quantificati n of (B) ACC Ser79, (C) Akt Ser473 and Thr308
s l i li t or Akt ( ean ± . . , ** p < . rel ti t
a se ce of ins lin. . l ti t f .
To exa ine the relationship between AMPK activation and inhibition of insulin-stimulated
Akt phosphorylation by A769662, the concentration dependence of either effect of A769662 was
assessed. Significant A769662-mediated stimulation of ACC phosphorylation was achieved with
50–100 µM A769662 (Figure 3A,B). A769662 decreased both insulin-stimulated Akt Ser473 and
Thr308 phosphorylation in HUVECs in a concentration-dependent manner (Figure 3A), whereby
100 µM A769662 significantly inhibited Akt S473 phosphorylation and the statistical significance of
insulin-stimulated Akt phosphorylation at either site was lost at concentrations above 10 µM A769662
(Figure 3C,D).
Further ore, the ti e dependence of the inhibitory effect of A769662 on insulin-sti ulated Akt
phosphorylation was assessed. A769662 (50 µM) rapidly stimulated ACC phosphorylation in HUVECs
within 5 min, an effect that was sustained for at least 2 h (Figure 3E,F). The inhibitory effect of A769662
on insulin-stimulated Akt Ser473 phosphorylation occurred similarly rapidly within 5 min and was
sustained for 1 h (Figure 3E,G).
To deter ine hether the inhibition of insulin-sti ulated Akt phosphorylation in ECs as
A PK-dependent, si ilar experi ents ere conducted after prior incubation in the SBI-0206965,
hich has recently been described as a selective inhibitor of A PK [32]. Preincubation ith 30 µ
SBI-0206965 co pletely inhibited A769662-stimulated ACC Ser79 phosphorylation (Figure 4A,B),
yet had no effect on the inhibition of insulin-stimulated Akt phosphorylation at Ser473 or Thr308
(Figure 4A,C,D), further indicating that the inhibitory effect of A769662 was AMPK-independent.
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Figure 3. A769662 decreases Akt phosphorylation in a concentration- and time-dependent manner in 
HUVECs. HUVECs were stimulated with (A–D) the indicated concentrations of A769662 for 45 min 
or (E–G) 50 µM A769662 for the indicated durations prior to insulin (1 µM, 15 min). Cell lysates were 
prepared and immunoblotted with the antibodies indicated. (A,E) Representative immunoblots from 
three independent biological replicates with molecular weight markers indicated. Total ACC protein 
level was assessed by stripping and re-probing the membranes. Densitometric quantification of (B,F) 
ACC Ser79, (C,G) Akt Ser473 and (D) Akt Thr308 phosphorylation (mean ± SEM). * p < 0.05, ** p < 
0.01, *** p < 0.001, **** p < 0.0001 relative to absence of insulin. # p < 0.05, ## p < 0.01, ### p < 0.001 
relative to absence of A769662. 
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Figure 4. SBI-0206965 inhibits A769662-stimulated AMPK activation without altering inhibition of 
insulin-stimulated Akt phosphorylation in HUVECs. HUVECs were stimulated with A769662 (50 µM, 
45 min) prior to insulin (1 µM, 15 min) after preincubation in the presence or absence of SBI-0206965 
(SBI, 30 µM, 30 min) and cell lysates prepared. Proteins were resolved by SDS-PAGE and 
immunoblotted with the antibodies indicated. (A) Representative immunoblots from six biological 
replicates with molecular weight markers indicated. Densitometric quantification of (B) ACC, (C) Akt 
Ser473 and (D) Akt Thr308 phosphorylation normalised to total ACC or Akt (mean ± SEM). * p < 0.05, 
** p < 0.01, *** p < 0.001, **** p < 0.0001 relative to absence of insulin. ## p < 0.01, ### p < 0.001, #### 
relative to absence of A769662. $$ p < 0.01, $$$ p < 0.001, $$$$ p < 0.0001 relative to absence of SBI-
0206965. 
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To determine whether this inhibition of insulin signalling was conserved in ECs from other 
regions of the vasculature, insulin-stimulated NO synthesis and signalling were assessed in HAECs. 
A769662 (50 µM) markedly inhibited insulin-stimulated NO synthesis (Figure 5A), an effect 
associated with reduced insulin-stimulated phosphorylation of Akt Ser473 (Figure 5B,C). To examine 
whether insulin signalling through an alternative pathway independent of PI3K was influenced by 
A769662, insulin-stimulated Erk1/2 phosphorylation was assessed. Intriguingly, A769662 
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2.2. Insulin Signalling and Insulin-Stimulated NO Production are Significantly Decreased in
A769662-Treated HAECs
To determine whether this inhibition of insulin signalling was conserved in ECs from other
regions of the vasculature, insulin-stimulated NO synthesis and signalling were assessed in HAECs.
A769662 (50 µM) markedly inhibited insulin-stimulated NO synthesis (Figure 5A), an effect associated
with reduced insulin-stimulated phosphorylation of Akt Ser473 (Figure 5B,C). To examine whether
insulin signalling through an alternative pathway independent of PI3K was influenced by A769662,
insulin-stimulated Erk1/2 phosphorylation was assessed. Intriguingly, A769662 significantly inhibited
insulin-stimulated Erk1/2 phosphorylation (Figure 5B,D).
To examine whether the inhibitory action of A769662 on insulin-stimulated Akt phosphorylation
was observed in non-endothelial cell lines, similar experiments were conducted in the HeLa tumour
and HepG2 hepatoma cell lines. Preincubation with A769662 (50 µM, 45 min) or compound 991
(5 µM, 60 min) significantly increased ACC Ser79 phosphorylation in both HeLa (Supplementary
Figure S2) and HepG2 cells (Supplementary Figure S3) to a similar extent. Unlike HUVECs,
preincubation with A769662 had no statistically significant effect on basal or insulin-stimulated Akt
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Ser473 phosphorylation in either cell line, although the statistical significance of the effect of insulin was
lost upon preincubation with A769662 in HeLa cells (Supplementary Figure S2C,D). Compound 991 did
not affect insulin-stimulated Akt Ser473 and Thr308 phosphorylation in HepG2 cells (Supplementary
Figure S3C,D) yet intriguingly did increase insulin-stimulated Akt Ser473 and Thr308 phosphorylation
in HeLa cells (Supplementary Figure S2C,D). The inhibition of insulin-stimulated Akt Ser473
phosphorylation by preincubation with A769662 therefore seems to be restricted to ECs, and it is not
observed in insulin-sensitive human cell lines.Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  7 of 17 
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durations. Cell lysates were prepared and immunoblotted with the antibodies indicated. (B) 
Representative immunoblots from three independent biological replicates with molecular weight 
markers indicated. (C,D) Densitometric quantification (mean ± SEM) of (C) Akt Ser473 or (D) Erk1 
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Figure 5. The effect of A769662 on insulin-stimulated NO synthesis and signalling in HAECs.
(A) HAECs were stimulated with the indicated concentrations of A769662 prior to insulin stimulation
(1 µM, 15 min). Conditioned media was collected and NO production assessed. (B–D) HAECs were
incubated with 50 µM A769662 for 45 min prior to insulin stimulation (1 µM) for the indicated durations.
Cell lysates were prepared and immunoblotted with the antibodies indicated. (B) Representative
immunoblots fro three independent biological replicates with molecular weight markers indicated.
(C,D) Densitometric quantification (mean ± SEM) of (C) Akt Ser473 or (D) Erk1 Thr202/Tyr204
p osphorylation normalised to total Akt or Erk1 levels respectively (mean± SEM). * p < 0.05, ** p < 0.01
relative to absence of insulin. # p < 0.05, relative to absence of A769662.
2.3. A769662 Inhibits Insulin-Stimulated Erk1/2 Phosphorylation in an AMPK-Independent Manner
To further assess the AMPK-dependence of the inhibition of insulin-stimulated Akt and Erk1/2
phosphorylation by A769662, SV40-immortalised wild-type (WT) or AMPK knockout (KO) mouse
embryonic fibroblasts (MEFs) [33] were stimulated with insulin after prior incubation in the presence or
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absence of A769662 (Figure 6). A769662 (100 µM, 30 min) robustly stimulated ACC phosphorylation in
WT MEFs and ACC phosphorylation was undetectable in KO MEFs (Figure 6A). Insulin stimulated Akt
Ser473 and Erk1/2 phosphorylation to a similar extent in cells from either genotype, yet A769662 had
no effect on insulin-stimulated Akt Ser473 phosphorylation in either genotype (Figure 6B). In contrast,
insulin-stimulated Erk1/2 phosphorylation was significantly inhibited by preincubation with A769662
in cells of either genotype (Figure 6C), indicating an AMPK-independent effect.
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2.4. A769662 Inhibits IGF1-Stimulated Akt Ser473 Phosphorylation but Has No Effect on VEGF Signalling
To examine whether A769662 inhibits Akt phosphorylation in response to growth factors other
than insulin in ECs, the effect of A769662 on IGF-1 and VEGF were assessed in HUVECs. VEGF
(10 ng/mL, 10 min) stimulated a significant increase in Erk1 Thr202/Tyr204 phosphorylation, yet
there was only a trend towards an increase in Akt Ser473 phosphorylation (Figure 7). In contrast,
IGF1 (25 ng/mL, 10 min) significantly stimulated Akt Ser473 phosphorylation and tended to increase
Erk1 Thr202/Tyr204 phosphorylation (Figure 7). Preincubation with A769662 significantly increased
ACC Ser79 phosphorylation (Figure 7B) and modestly inhibited IGF1-stimulated Akt phosphorylation
(Figure 7C). Although previous studies from our laboratory have shown VEGF stimulated AMPK
activity after 5 min [34,35], stimulation with VEGF for 10 min only tended to increase ACC Ser79
phosphorylation in HUVECs (Figure 7B). This disparity may reflect the difference in incubation
time, as in previous studies, VEGF stimulated transient ACC Ser79 phosphorylation that reached a
maximum at 5 min and decreased rapidly after this point [34]. Furthermore, in contrast to the inhibitory
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action of A769662 on insulin-stimulated Erk1/2 phosphorylation observed in HAECs (Figure 5), IGF-1
significantly stimulated Erk1/2 phosphorylation only in the presence of A769662 (Figure 7D).
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Figure 7. 769662 tends to attenuate IGF1-stimulated Ser473 Akt phosphorylation but has no effect on
VEGF signalling in HUVECs. HUVECs were stimulated with A769662 (50 µM 45 min) prior to VEGF
(10 ng/mL, 10 min) or IGF1 (25 ng/mL, 10 min). Cell lysates were prepared, proteins resolved by
SDS-PAGE and immunoblotted with the antibodies indicated. (A) Representative immunoblots from
four indepe nt biological replicat s with molecular weight markers indicated. Total ACC protein
level was assessed by tripping and re-probing the membranes. (B–D) De sitometric quantification
of (B) ACC Ser79, C kt Ser473 or (D) Erk1 Thr202/Tyr204 phosp orylation normalised to total
ACC, Akt or α- ubulin levels respec ively (m an ± SEM). * p < 0.05, ** p < 0.01, *** p < 0.001 relative to
absence of IGF1/VEGF. # p < 0.05, #### p < 0.0001 relative to absence of A769662.
2.5. AMPK Complexes Containing α1 and β1 Isoforms Contribute the Majority of Total Cellular AMPK
Activity in HAECs
A769662 and compound 991 selectively activate AMPK complexes containing the β1 regulatory
subunit [31]. It has previously been demonstrated that HepG2 cells principally express AMPKβ1,
whereas HeLa cells express both AMPKβ1 and AMPKβ2 [36], yet the proportion of AMPKβ1/β2
complexes in endothelial cells has not been reported. The activities of AMPK complexes containing
specific AMPKβ and α isoforms was therefore assessed in HAECs. Complexes containing AMPKβ1
accounted for approximately 60% of the total cellular AMPK activity and AMPKβ2 the remaining 40%
in HAECs. As previously reported, complexes containing AMPKα1 represent the majority (~95%) of
total cellular AMPK activity in HAECs [21] (Figure 8).
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3. Discussion
This study demonstrates that A769662 inhibited the effects of insulin on Akt phosphorylation
and NO synthesis in ECs, but had no substantive effect on Akt phosphorylation in MEFs, HeLa or
HepG2 cells. This action of A769662 was not attenuated when AMPK activity was inhibited, and was
not recapitulated by the alternative AMPK activators compound 991 and AICAR, suggesting this is
an AMPK-independent action of A769662. In addition, A769662 inhibited insulin-stimulated Erk1
phosphorylation in ECs and MEFs, an effect that was still apparent in MEFs lacking AMPK activity.
Taken together, these data suggest an EC-specific action of A769662 on early insulin signalling that is
independent of AMPK.
Previous studies have demonstrated multiple beneficial effects of AMPK activation on insulin
signalling, lipid and plasma glucose levels [17,23,37,38]. In ECs, AMPK activation has been reported
to stimulate NO synthesis and angiogenesis while inhibiting pro-inflammatory signalling and reactive
oxygen species synthesis [10]. Most of these studies have used AMPK activators that either indirectly
activate AMPK through the inhibition of mitochondrial ATP synthesis, such as metformin, berberine
and resveratrol or mimic AMP, such as AICAR [39]. As a consequence, these AMPK activators also have
numerous other effects that are not mediated by AMPK. In contrast, A769662 and compound 991 are
direct allosteric activators of AMPK that selectively or show a bias toward activating AMPK complexes
containing the β1 regulatory subunit isoform [31]. Few studies have examined the endothelial effects
of A769662, although it has been reported to inhibit antioxidant gene expression [40,41], viability and
proliferation [13,32] and proinflammatory signalling [12,42] in human ECs. Furthermore, compound
991 has been also reported to inhibit proinflammatory signalling in ECs [12].
It is, therefore, surprising that A769662 inhibited insulin-stimulated NO synthesis in HUVECs
and HAECs, as many studies report that AMPK activation stimulates NO synthesis [10]. Indeed,
A769662 stimulates activating eNOS Ser1177 phosphorylation in hearts and AICAR and resveratrol
have been reported to improve impaired insulin-mediated vascular responses in rodents [43–45].
Endothelial AMPK activation is not always associated with eNOS phosphorylation or NO synthesis,
however [46,47], and the lack of insulin-stimulated NO synthesis in A769662-stimulated HAECs and
HUVECs is likely to be a consequence of reduced insulin-stimulated Akt phosphorylation, since Akt
is required for the activation of eNOS by insulin [48]. A769662 also decreased IGF1-stimulated Akt
phosphorylation. Insulin and IGF1 both activate Akt [49], differing only in the initial step, as they
bind to the insulin receptor (IR) and IGF1 receptor (IGF1R) respectively. In addition, IGF1R and
IR share enough structural similarity to allow interchangeable binding of IGF1 and insulin [49,50].
Although IGF1 has a higher affinity for IGF1R, IGF1 may still bind IR and vice-versa. This may explain
why A769662 seems to have a more modest effect on IGF1-stimulated Akt Ser473 phosphorylation,
as IGF1 signalling may recruit distinct populations of IR substrate (IRS) proteins compared to
insulin [51]. On the other hand, unlike insulin and IGF1, VEGF signalling does not utilise IRSs
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to recruit PI3K and was unaffected by A769662 preincubation [52]. As both Akt Ser473 and Thr308
phosphorylation were inhibited by A769662 in ECs, this suggests that A769662 does not simply inhibit
the kinases that phosphorylate those sites, mammalian target of rapamycin complex 2 (mTORC2)
or phosphoinositide-dependent protein kinase-1 (PDK1) respectively [2]. In addition, A769662 also
inhibited insulin-stimulated Erk1/2 phosphorylation in ECs and MEFs, which is activated by a
pathway separate to that of Akt after insulin receptor activation [53]. Importantly, A769662 also
inhibited insulin-stimulated Erk1/2 phosphorylation in MEFs lacking AMPK, demonstrating that this
effect is AMPK-independent. A769662 has previously been demonstrated to have no direct effect on
the activity of Akt or PDK1, although it did inhibit the Erk1 kinase, mitogen-activated protein kinase
kinase-1 (MKK1), in vitro [54]. In contrast, IGF-1-stimulated Erk1 phosphorylation was accentuated
by A769662 in HUVECs, such that direct inhibition of MKK1 by A769662 may not simply underlie
the inhibition of insulin-stimulated Erk1/2 phosphorylation. Taken together, these data indicate that
A769662 inhibits at the level of the insulin/IGF-1 receptor or a receptor-associated protein, thereby
inhibiting both pathways.
The inhibition of insulin-stimulated Akt phosphorylation by A769662 in ECs was not recapitulated
by either compound 991 or AICAR, both of which activate AMPK to a similar degree. Compound
991 allosterically activates AMPK at a similar site to A769662 [31], whereas AICAR is phosphorylated
to the AMP-mimetic, ZMP within cells [39]. Indeed, AICAR increased basal and insulin-stimulated
Akt phosphorylation in ECs, in agreement with previous reports [15,21]. As both Akt Ser473 and
Thr308 phosphorylation increased, this likely reflects stimulation of PI3K or earlier signalling events by
AICAR, independent of AMPK activation. Given that the inhibition of Akt phosphorylation was still
observed in ECs in which AMPK activity had been completely inhibited by SBI-0206965 and the lack of
effect of compound 991 despite the similar mechanism by which compound 991 activates AMPK, these
data indicate an AMPK-independent action of A769662 on insulin-stimulated Akt phosphorylation,
although it occurs with a similar concentration to that required for AMPK activation.
Intriguingly, the inhibitory effect of A769662 on insulin-stimulated Akt activation was limited
to ECs, as it was not observed in MEFs, HeLa or HepG2 cells, although the statistical significance
of stimulation by insulin was lost in HeLa cells preincubated with A769662. A769662 (100 µM) has
been demonstrated previously to inhibit basal Akt Ser473 phosphorylation in prostate cancer cell
lines, yet stimulated Akt Ser473 phosphorylation at a lower concentration (50 µM) [55]. Indeed,
previous studies have shown no effect of A769662 on insulin-stimulated Akt activation in rat adult
cardiomyocytes, human myotubes or L6 cells [29,56,57]. In contrast to this neutral effect reported in
striated muscle cells, A769662 has also been reported to stimulate glucose uptake in muscle cells by
increasing PI3K association with IRS1, suggesting an AMPK-independent effect that increased Akt
activity [58]. In addition, high concentrations of A769662 stimulated Akt phosphorylation in a manner
sensitive to the PI3K inhibitor, wortmannin in CHO cells expressing the δ-opioid receptor [59]. It is
clear, therefore, that A769662 influences Akt differentially in different cell types, providing further
evidence that these effects are not mediated by AMPK.
In addition, we demonstrate that preincubation of HeLa cells, but not HepG2 cells or ECs, with
compound 991 increased insulin-stimulated Akt phosphorylation. These data argue for a cell-type
specific/selective effect of A769662 on insulin signalling, whereby only A769662 markedly reduces
insulin signalling in ECs and insulin-stimulated Erk1/2 phosphorylation in ECs and MEFs. This
cell-type selectivity could be related to differential expression of IR/IGF1R between cell types. HUVECs
have been previously reported to have approximately 400,000 IGF1R/cell and 40,000 IR/cell [30].
Furthermore, according to the updated version of Human Protein Atlas (https://www.proteinatlas.
org/) [60], HepG2 and HeLa cells have been reported to express 21.9 and 27.5 IGF1R transcripts per
million (TPM), respectively and 15.9 and 1.9 IR TPM respectively [61]. Higher IR levels could preserve
insulin-stimulated Akt and Erk1 phosphorylation by increasing the number of activated receptors
and signal intensity. The high relative IR expression levels in HepG2 cells may therefore explain why
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A769662 had no effect on attenuation of insulin signalling in this cell line, whereas in HUVECs and
HAECs, which have lower IR expression levels, there was such a marked effect of A769662.
It is unlikely that the differential effects of A769662 in the different cell types can be explained
by differences in AMPK isoform expression, due to the selectivity of A769662 and compound
991 [31]. Both compounds would be expected to activate AMPK complexes containing β1, and
complexes containing AMPKβ1 were found to contribute ~60% of the total cellular AMPK activity
in HAECs. It has previously been reported that HepG2 cells principally express AMPKβ1, whereas
HeLa cells express both AMPKβ1 and AMPKβ2 [36]. This further indicates that the inhibition of
insulin signalling in ECs by A769662 is an AMPK-independent effect and unrelated to differential
actions on specific pools of AMPK within ECs, as all the cell types investigated express abundant
AMPKβ1 levels. As AMPK-independent effects of A769662, including inhibition of 26S proteasome
activity in MEFs, voltage-gated Na+ channels in rat neurons and the Na+/K+ ATPase in L6
cells [26,28,29] have been reported previously, inhibition of insulin signalling in ECs may similarly be
considered AMPK-independent. In addition, A769662 was recently reported to promote vasorelaxation
in rabbit and rat arteries by reducing cytosolic Ca2+ levels, by an endothelium-dependent yet
AMPK-independent manner [62].
In conclusion, A769662 decreases insulin-stimulated NO synthesis and Akt Ser473
phosphorylation in HUVECs and HAECs in a manner likely to be independent of AMPK. Furthermore,
A769662 decreases insulin-stimulated Erk1/2 phosphorylation in a manner that is AMPK-independent
in MEFs and HAECs. Taken together, these data demonstrate that caution should be exercised when
interpreting data obtained using A769662 as a tool in cultured human endothelial cells.
4. Materials and Methods
4.1. Materials
Cryopreserved HUVECs, HAECs and MV2 medium were purchased from Promocell (Heidelberg,
Germany). SV40-immortalised wild-type and AMPKα1 and AMPKα2 knock-out MEFs were kindly
provided by Dr. B. Viollet (Institut Cochin, Paris, France) and have been described previously [33].
HeLa and HepG2 cells were obtained from ATCC (Manassas, VA, USA). IGF1, VEGF, SBI-0206965 and
porcine insulin were purchased from Sigma Aldrich (St. Louis, MO, USA). AICAR was purchased
from Toronto Research Chemicals Inc. (Ontario, ON, Canada). Compound 991 was synthetised
by MRC Technology. A769662 and mouse anti-β-tubulin (#11307) antibodies were purchased from
Abcam (Cambridge, UK). Rabbit anti-phospho-Akt Thr308 (#13038), anti-phospho-Akt Ser473 (#4058),
anti-ERK1/2 (#9102), anti-phospho-ACC Ser79 (#3661), anti-ACC (#3676), anti-α-tubulin (#2144) and
mouse anti-Akt (#2920) and anti-phospho-p44/42 Erk1/2 (Thr202/Tyr204) (#9106) antibodies were
from New England Biolabs UK (Hitchin, UK). Sheep anti-AMPKα1, anti-AMPKα2, anti-AMPKβ1
and anti-AMPKβ2 antibodies used for immunoprecipitation of AMPK complexes containing specific
subunit isoforms were a kind gift from Professor D.G. Hardie (University of Dundee) and have been
described previously [39,63,64]. IRdye680 or 800-labelled donkey anti-mouse IgG (#926-32212) and
anti-rabbit IgG (#926-68023 and #926-32213) antibodies were from LI-COR Biosciences (Lincoln, UK).
Medium 199, RPMI 1640 and DMEM (4.5 g/L glucose) were from Life Technologies (Paisley, UK).
4.2. Cell Culture and Experimental Design
HAECs and HUVECs were cultured in MV2 medium supplemented with EC growth factor mix,
5% (v/v) serum (Promocell). HUVECs and HAECs were utilised between passages 3 and 6. MEFs
and HeLa cells were cultured in DMEM supplemented with 10% (v/v) foetal calf serum. HepG2 cells
were cultured in RPMI 1640 supplemented with 10% (v/v) foetal calf serum, 1 mM sodium pyruvate.
Once cells reached 90–100% confluence, HUVECs/HAECs were incubated in serum-free Medium 199
and HeLa cells and HepG2 cells were incubated with serum-free DMEM for 2 h and then with AMPK
activators prior to stimulation with insulin (1 µM), VEGF (10 ng/mL) or IGF1 (25 ng/mL). Cells were
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placed on ice and washed with PBS prior to lysis in Triton X-100-based lysis buffer (50 mM Tris-HCl,
pH 7.4 at 4 ◦C, 50 mM NaF, 1 mM Na4P2O7, 1 mM EDTA, 1 mM EGTA, 1% (v/v) Triton-X-100, 250 mM
mannitol, 1 mM DTT, 1 mM Na3VO4, 0.1 mM benzamidine, 0.1 mM PMSF, 5 µg/mL SBTI). Cell
lysates were scraped into microcentrifuge tubes and incubated on ice for 20 min, centrifuged (5 min,
21,910× g, 4 ◦C) and the subsequent supernatants stored at −20 ◦C. Lysate protein concentrations
were determined using Bradford or BCA methods, as previously described [6,21].
4.3. SDS-Polyacrylamide Gel Electrophoresis and Immunoblotting
Cell lysate proteins were resolved by SDS-PAGE and immunoblotted with antibodies diluted in
50% (v/v) LI-COR blocking buffer in TBS containing 0.1% (v/v) Tween-20 as described previously [13].
Proteins were visualised using infrared dye-labelled secondary antibodies on a LI-COR Odyssey
infrared imaging system and analysed using the ImageJ software for densitometric quantification of
band intensity. In some cases, indicated in the figure legends, immunoblots were stripped in 0.2 M
NaOH for 10 min, washed multiple times with Tris-buffered saline (TBS) until the pH returned to 7.2,
and then blocked in TBS supplemented with 5% (w/v) milk powder prior to probing with primary
antibodies. In all other cases, immunoblots for phospho- and total protein levels of ACC, Akt and
Erk1/2 were obtained on immunoblots conducted concurrently in parallel.
4.4. NO Assay
HAECs and HUVECs were cultured in 6-well plates until 100% confluent and serum-starved
for 2 h in Medium 199 and then in the presence of Krebs-Ringer-Hepes (KRH) buffer for 20 min.
The medium was replaced and cells incubated in the presence or absence of stimuli in KRH for a
further 15–20 min. Samples of medium (50 µL) were taken at different intervals and 200 µL methanol
added to each. Samples were centrifuged (21,910× g, 4 ◦C, 20 min), and supernatants were stored
at −20 ◦C. NO concentration was determined using a Sievers 280A NO Meter (Sievers, Boulder, CO,
USA) as described previously [21].
4.5. AMPK Assay
AMPK specific isoforms were immunoprecipitated from HAECs using sheep anti-AMPKα1,
anti-AMPKα2 [63], anti-AMPKβ1 [39] or anti-AMPKβ2 [64] antibodies bound to protein G-Sepharose
(1 µg antibody and 5 µL packed volume protein G-Sepharose/immunoprecipitation) in IP buffer
(50 mM Tris-HCl (pH 7.4 at 4 ◦C), 150 mM NaCl, 50 mM NaF, 5 mM Na4P2O7, 1 mM EDTA, 1 mM
EGTA, 1% (v/v) Triton-X-100, 1% (v/v) glycerol, 1 mM DTT, 0.1 mM benzamidine, 1 mM PMSF,
5 µg/mL SBTI, 1 mM Na3VO4). Immunoprecipitates were then washed into HBD buffer (50 mM
HEPES-NaOH (pH 7.4), 0.02% (v/v) Brij-35, 1 mM DTT) and assayed for AMPK activity using SAMS
substrate peptide as described previously [12,35].
4.6. Statistical Analysis
All data is expressed as a relative change (mean ± SEM) from control baseline or normalised to
group of reference for each experiment. Prism software (GraphPad Software, San Diego, CA, USA) was
used to perform one or two-way ANOVA (with Tukey’s or Dunnett’s post hoc multiple comparison
tests), where appropriate, using p < 0.05 as significant.
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